Knight Therapeutics Inc. announced the resignation of Ed Schutter and the appointment Dr. Sarit Assouline to Knight's Board of Directors. Dr. Sarit Assouline MD, MsC, FRCPC, since 2005, she has been involved in the design and conduct of numerous clinical trials testing novel therapies in patients with leukemia and lymphoma.